February 26, 2025—Humacyte, Inc. announced the commercial launch of Symvess, an acellular tissue engineered vessel-tyod (ATEV) indicated for use

Humacyte (HUMA) has launched Symvess, its FDA-approved bioengineered human tissue vascular conduit, for treating extremity arterial injuries. The product received full FDA approval on December 19, 2024, and is now authorized for commercial shipments.Twenty-one hospitals have initiated the Value Analysis Committee (VAC) approval process, with two already completing their review and approving Symvess purchases. Some hospitals plan to purchase while VAC review is ongoing. The product has shown positive results in clinical studies, including high patency rates and low amputation and infection rates.According to Humacyte's Budget Impact Model (BIM), Symvess treatment is estimated to be more cost-effective than synthetic grafts, cryopreserved allografts, or xenografts, primarily due to reduced amputation and infection rates.

Humacyte achieves landmark FDA approval for SYMVESS, the first bioengineered vascular conduit for urgent arterial injury treatment, backed by strong clinical data and battlefield success.

Humacyte (Nasdaq: HUMA) announced the publication of a Budget Impact Model (BIM) for Symvess in the Journal of Medical Economics. Symvess, a bioengineered human tissue for vascular repair, received FDA approval on December 19, 2024.The economic analysis reveals significant cost savings for both trauma centers and payers. For trauma centers, the average per-patient cost with Symvess is $121,615 (including $29,500 purchase price), compared to $154,722 for cryopreserved allograft, $140,428 for bovine xenograft, and $137,213 for prosthetic grafts. For commercial payers, Symvess costs $94,165 per patient versus $181,127 for prosthetic grafts.Cost savings are primarily attributed to reduced rates of vascular conduit infection and amputation. The model incorporated data from the PROOVIT registry, hospital charges, insurance claims, and expert opinion.

The FDA has approved Symvess, a pioneering acellular tissue engineered vessel designed to treat vascular trauma in adults, offering a novel solution for urgent medical needs.

Humacyte (Nasdaq: HUMA) on April 24, 2026 realigned ex-U.S. commercial rights to Symvess through an amended distribution agreement with Fresenius Medical Care. The amendment grants Humacyte exclusive distribution rights outside the U.S., with Fresenius entitled to low-single-digit royalties on Humacyte's net non-U.S. sales. U.S. distribution terms remain unchanged. The realignment is intended to support Humacyte's planned international expansion, advance discussions with potential corporate partners for indication-specific and regional rights, and enable previously announced initiatives in the Kingdom of Saudi Arabia and Israel. For uses beyond the FDA-approved extremity vascular trauma indication, Symvess remains investigational and is not approved for sale by the FDA or other regulators.

Profit on the stock market by investing in biotech stocks

Hi, it’s Anna in Virginia. A month ago I wrote about a whistleblower who said FDA staff were pressured to approve a medical device. This wasn’t the end of the story, but before we get to that ...

Humacyte (Nasdaq: HUMA) reported Q1 2025 financial results and key business updates. The company achieved a major milestone with the commercial launch of Symvess™, its bioengineered vascular tissue product, generating first commercial sales of $147,000. Total revenue was $517,000, including $370,000 from a research collaboration. The company completed a $46.7 million public offering and implemented cost reductions, including a workforce reduction of 31 employees, targeting savings of $13.8 million in 2025 and up to $38 million in 2026. Currently, 45 hospitals have initiated the Value Analysis Committee approval process for Symvess, representing about 25% of all Level 1 trauma centers. The company reported net income of $39.1 million for Q1 2025, compared to a net loss of $31.9 million in Q1 2024, primarily due to non-cash remeasurement of contingent earnout liability. Cash position stood at $113.2 million as of March 31, 2025.

Humacyte (NASDAQ: HUMA) announced its Q4 and full-year 2024 financial results, highlighting the FDA approval of Symvess™ for extremity vascular trauma treatment in December 2024. The company has initiated commercial launch with first sales in February 2025, with 34 hospitals starting the Value Analysis Committee approval process and three hospitals already approving purchases.Financial highlights show no revenue for Q4 and full-year 2024. R&D expenses were $20.7M in Q4 2024 and $88.6M for the full year. Net loss increased to $148.7M for 2024, compared to $110.8M in 2023. The company reported $95.3M in cash and equivalents as of December 31, 2024, with an additional $46.6M raised through a public offering in March 2025.Key developments include positive Phase 3 trial results for arteriovenous access in dialysis patients, plans for a supplemental BLA submission in H2 2026, and an upcoming IND filing in 2025 for coronary artery bypass grafting studies.

The FDA has authorised doubling Symvess's expiry dating, easing hospital inventory management for the bioengineered vascular conduit approved in 2024.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Reported Wednesday, Sep 9 - 8:16am EDT (TheFly subscription required to read more.)

$HUMA Stock Hub: November 2026 dialysis sBLA plan, V012/V007 evidence, Symvess Q2 sales, cash burn, completed June financing, ownership and Nasdaq status.

Humacyte (Nasdaq: HUMA) announced that board-certified vascular and endovascular surgeon Jeromy Brink, MD, has performed the first post‑BLA‑approval Symvess implants in Arizona at Banner University Medical Center in Phoenix, completing four procedures within two weeks of gaining access to the product.Symvess, an FDA‑approved acellular tissue engineered vessel, is indicated as a vascular conduit for adults with extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and an autologous vein graft is not feasible. The off‑the‑shelf vessel is available on demand in the operating room. Humacyte highlights important safety information, including a boxed warning for graft failure, risks of graft rupture, anastomotic failure, thrombosis, and potential transmission of infectious diseases. Uses outside the approved extremity vascular trauma indication remain investigational.

Hi, it’s Anna in Virginia. A month ago I wrote about a whistleblower who said FDA staff were pressured to approve a medical device. This wasn’t the end of the story, but before we get to that ...

WASHINGTON, D.C. — A breakthrough in life-saving medical technology has arrived. The U.S. Food and Drug Administration (FDA) has officially approved Symvess, the first acellular tissue-engineered vess...